An informatics approach identifying markers of chemosensitivity in human cancer cell lines.

By S. Amundson, T. Myers, D. Scudiero, S. Kitada, John Calvin Reed, A. Fornace. Cancer Research, 2000

407 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Bcl-2 apoptotic switch in cancer development and therapy (2007, methodology): “For example, with the National Cancer Institute (NCI) panel of 60 diverse cancer cell lines, the expression level of Bcl-xL strongly correlates with resistance to most chemotherapy agents (Amundson et al., 2000).”
Apoptosis and Molecular Targeting Therapy in Cancer (2014, background): “Clinically, high levels of ERCC1 are correlated with poor response to platinum-based chemotherapy in ovarian, gastric, and nonsmall cell lung cancers (NSCLC) [184–186].”
Promoting apoptosis as a strategy for cancer drug discovery (2005, background): “In fact, cancer cell resistance to a panel of 122 chemotherapeutic agents strongly correlated with the expression levels of BCL-X L”
BCL-2 family antagonists for cancer therapy (2008, background): “Furthermore, levels of BCL-X L expression in the 60 cell lines in the National Cancer Institute's anticancer drug screen (NCI-ACDS) panel are highly correlated with resistance to 122 standard chemotherapeutic agent”